2005
DOI: 10.1542/peds.2004-1536
|View full text |Cite
|
Sign up to set email alerts
|

Letrozole Significantly Improves Growth Potential in a Pubertal Boy With Growth Hormone Deficiency

Abstract: ABSTRACT. Clinical experience with using an aromatase inhibitor to suppress estrogen production during puberty for improvement of growth potential in adolescents with short stature is limited. This report documents treatment of such a patient with a combination of growth hormone and letrozole, a third-generation aromatase inhibitor. Our case demonstrates a favorable outcome on a short-term basis. E strogen plays a critical role for the pubertal growth spurt, skeletal maturation, and accrual and maintenance of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2006
2006
2019
2019

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(11 citation statements)
references
References 20 publications
0
11
0
Order By: Relevance
“…Aromatase inhibition [93,[99][100][101][102] may be an effective means of enhancing growth in boys, with growth stimulated by the continued presence of androgen and bone age advancement slowed by elimination of estrogen. In a double-blind, placebo-controlled trial, the potent aromatase inhibitor, letrozole, was used to slow the rate of skeletal maturation in boys with short stature and delayed puberty who were also receiving testosterone [99,103].…”
Section: Aromatase Inhibitorsmentioning
confidence: 99%
“…Aromatase inhibition [93,[99][100][101][102] may be an effective means of enhancing growth in boys, with growth stimulated by the continued presence of androgen and bone age advancement slowed by elimination of estrogen. In a double-blind, placebo-controlled trial, the potent aromatase inhibitor, letrozole, was used to slow the rate of skeletal maturation in boys with short stature and delayed puberty who were also receiving testosterone [99,103].…”
Section: Aromatase Inhibitorsmentioning
confidence: 99%
“…In men, AIs have been, or are being, examined as potential therapies for breast cancer (Zabolotny et al 2005), gynecomastia (Plourde et al 2004;Riepe et al 2004;Boccardo et al 2005;Rhoden and Morgentaler 2004), hypogonadism (Dougherty et al 2005;Leder et al 2004;Holbrook and Cohen 2003), short stature and bone metabolism in pubertal boys (Mauras et al 2004;Zhou et al 2005;Dunkel and Wickman 2003;Wickman et al 2003), epilepsy (Harden and MacLusky 2004), infertility (Raman and Schlegel 2003), and androgenindependent prostate carcinoma (Smith et al 2003;Santen et al 2001). …”
Section: Implications For Use Of Aromatase Inhibitorsmentioning
confidence: 99%
“…The discovery that estrogen mediates epiphyseal fusion has prompted interest in aromatase inhibitor treatment as a potential means to increase AH in other pediatric conditions associated with short stature, such as constitutional delay of growth and adolescence, 26 growth hormone deficiency, 27 and idiopathic short stature. 2832 Although the improved AH outcome in the current study of boys with FMPP is consistent with this potential, we agree with the recommendation to complete ongoing long-term clinical trials before expanding pediatric aromatase inhibitor treatment to a much wider patient group.…”
Section: Discussionmentioning
confidence: 99%